entertainment -WSS

entertainment

author：fashion 2025-09-05 13:47:46 - browse：64459

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Francis Collins on trust in science and how Covid communications failed

hotspot

WSS

How neuroscience research could help beat back brain cancer

New brain studies show LSD's effects on the brain in full color

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Key Senate panel to consider PBM, drug pricing reform package

Readout Newsletter: Merck, J&J, and long Covid

The surgeon had a dilemma only a Nazi medical text could resolve

focus

entertainment

focus

Medicare details structure of new drug price negotiation program

FDA clears AI tool for detecting skin cancer

BioMarin wins approval for gene therapy to treat hemophilia A

Infant mortality in U.S. rose last year for first time in decades: CDC

What does generative AI mean for health care? We asked experts

Inari Medical to buy amputation prevention company LimFlow

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

AI generated plenty of interest at JPM but not a lot of trust

hotspot

Parkinson’s finding may lead to tests and, someday, treatments

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Prime Medicine says its gene editing passes test in monkeys

Readout LOUD podcast: ESMO highlights & Roivant's big deal

The health care issue Democrats can’t solve: hospital reform

Gene therapy’s promise and the high cost of hope

hotspot

leisure time

focus

focus